Nanomedicine in Cancer Therapy: From Preclinical Promise to Clinical Applications

Background: Cancer continues to be a predominant worldwide health problem, characterized by rising incidence and fatality rates. Conventional therapies, including chemotherapy, gene therapy, and immunotherapy, exhibit limitations such as inadequate targeting, drug degradation, and unwanted effects. Nanomedicine has intriguing methods to address these difficulties by enhancing drug delivery and targeting. Methods: This review examines the incorporation of nanomedicine in cancer treatments, emphasizing chemotherapy, gene therapy, and immunotherapy. We examine the application of nanoparticulate delivery systems (NDSs) to improve drug delivery, augment tumor targeting, and minimize adverse effects. Numerous nanomaterials, including organic, inorganic, and composite nanoparticles, are analyzed for their potential to overcome the constraints of traditional therapies. Results: Nanomedicine has shown a lot of promise in improving the pharmacokinetics of chemotherapeutic drugs, making gene delivery more effective, and boosting immune responses in cancer immunotherapy. Pharmaceuticals can be delivered precisely and safely with nanoparticles, which solve problems like poor solubility, instability, and poor cell absorption in neoplasms. Conclusion: The use of nanomedicine in oncological treatment demonstrates significant promise for enhancing therapeutic results. Even though there are still issues with turning preclinical findings into clinical applications, nanotechnology is making steady progress that will enhance the effectiveness of chemotherapy, gene therapy, and immunotherapy, opening new ways to customize cancer treatment.